KPRX
Kiora Pharmaceuticals, Inc.
Kiora Pharmaceuticals, Inc. (KPRX) is currently in a range/mixed trend, above the 200-day MA but below the 50-day MA. RSI is at 43.4, with 2/3 trend checks passing.
KPRX with MA50 and MA200
Key levels & signals
Kiora Pharmaceuticals, Inc. (KPRX) looks more range-bound than strongly trending, but there are still a few supportive signs on the chart. The latest available price is $2.48, and 2 of 3 core trend checks are currently passing. Price is trading below the 50-day moving average by 3.8% and above the 200-day moving average by 6.9%.
KPRX currently has an RSI reading of 43.4, which leans a little softer than neutral. That does not automatically make the chart bearish, but it does suggest momentum is not especially strong right now.
This page is designed to help you quickly understand what the KPRX chart looks like before opening the full dashboard. The aim is not to tell you what to buy or sell, but to make it easier to judge whether the stock is trending cleanly, becoming stretched, or simply moving in a more awkward range.
About Kiora Pharmaceuticals, Inc.
Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candidate, KIO-301, is a groundbreaking small molecule undergoing Phase 1 clinical trials. This innovative "photoswitch" aims to revitalize vision in individuals suffering from both inherited and age-related forms of retinal degeneration. The company's pipeline also includes KIO-101, an eye drop currently in Phase 2 trials for addressing the ocular manifestations of rheumatoid arthritis, as well as non-infectious posterior uveitis. Furthermore, Kiora is advancing KIO-201, another eye drop, which is in Phase 3 clinical trials, designed to facilitate corneal wound healing following PRK surgery. Established in 1998, the company adopted its current name in November 2021, having previously operated as Eyegate Pharmaceuticals, Inc. Kiora Pharmaceuticals maintains its corporate headquarters in Salt Lake City, Utah.
Learn the indicators behind this page
More stock opportunities
Common questions about KPRX
Is this page a buy or sell recommendation?
No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.
Why can a stock look bullish and overbought at the same time?
Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.
What should I do next after reading this page?
Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.